Serous ovarian tumors of low malignant potential (SLMP)--also called borderline tumors of the ovary--represent a heterogeneous group of ovarian epithelial neoplasms. In general, this tumor type ...
Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently ...
Researchers at Peter Mac have uncovered potential new heredity genes that might be responsible for causing one of the most ...
An NDA has been accepted by the FDA for the combination of avutometinib and defactinib in KRAS-mutated recurrent low-grade serous ovarian cancer. In the cancer world — or anywhere — the ability to ...
"We ended 2024 having made tremendous progress across our pipeline programs, including FDA acceptance of our NDA with ...
News Medical on MSN7d
Real-world effectiveness and safety of olaparib in HRD-positive BRCA wild-type ovarian cancerOvarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...
Avutometinib and defactinib target KRAS-mutated recurrent low-grade serous ovarian cancer, potentially becoming the first FDA-approved treatment for this specific cancer type. The NDA is supported by ...
FIGO Stage: A classification system used to describe the extent of cancer spread, developed by the International Federation of Gynecology and Obstetrics. Low-Grade Serous Carcinoma (LGSC): A type ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback